These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 25934816)

  • 1. Toward precision medicine in glioblastoma: the promise and the challenges.
    Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM
    Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma targeted therapy: updated approaches from recent biological insights.
    Touat M; Idbaih A; Sanson M; Ligon KL
    Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.
    Bastien JI; McNeill KA; Fine HA
    Cancer; 2015 Feb; 121(4):502-16. PubMed ID: 25250735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.
    Venkatesan S; Lamfers ML; Dirven CM; Leenstra S
    CNS Oncol; 2016; 5(2):77-90. PubMed ID: 26986934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SnapShot: glioblastoma multiforme.
    Kotliarova S; Fine HA
    Cancer Cell; 2012 May; 21(5):710-710.e1. PubMed ID: 22624719
    [No Abstract]   [Full Text] [Related]  

  • 7. Toward Personalized Targeted Therapeutics: An Overview.
    Weathers SS; Gilbert MR
    Neurotherapeutics; 2017 Apr; 14(2):256-264. PubMed ID: 27995437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the molecular classification of glioblastoma to inform personalized treatment.
    Olar A; Aldape KD
    J Pathol; 2014 Jan; 232(2):165-77. PubMed ID: 24114756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma precision therapy: From the bench to the clinic.
    Zhou Y; Wu W; Bi H; Yang D; Zhang C
    Cancer Lett; 2020 Apr; 475():79-91. PubMed ID: 32004571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI study identifies three subtypes of glioblastoma.
    Brower V
    Lancet Oncol; 2015 Oct; 16(13):e484. PubMed ID: 26365415
    [No Abstract]   [Full Text] [Related]  

  • 12. The challenges associated with molecular targeted therapies for glioblastoma.
    Jue TR; McDonald KL
    J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of molecular profiling on clinical trial design for glioblastoma.
    Chakravarti A; Tyndall E; Palanichamy K; Mehta M; Aldape K; Loeffler J
    Curr Oncol Rep; 2007 Jan; 9(1):71-9. PubMed ID: 17164051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using genomics to guide treatment for glioblastoma.
    Young JS; Prados MD; Butowski N
    Pharmacogenomics; 2018 Oct; 19(15):1217-1229. PubMed ID: 30203716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma: molecular analysis and clinical implications.
    Huse JT; Holland E; DeAngelis LM
    Annu Rev Med; 2013; 64():59-70. PubMed ID: 23043492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
    Weller M; Wick W; Hegi ME; Stupp R; Tabatabai G
    Future Oncol; 2010 Sep; 6(9):1407-14. PubMed ID: 20919826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
    Gan HK; van den Bent M; Lassman AB; Reardon DA; Scott AM
    Nat Rev Clin Oncol; 2017 Nov; 14(11):695-707. PubMed ID: 28675164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targets in glioblastoma.
    Zorzan M; Giordan E; Redaelli M; Caretta A; Mucignat-Caretta C
    Future Oncol; 2015; 11(9):1407-20. PubMed ID: 25952786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One size should not fit all: advancing toward personalized glioblastoma therapy.
    Reardon DA; Ligon KL; Chiocca EA; Wen PY
    Discov Med; 2015 Jun; 19(107):471-7. PubMed ID: 26175405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.